Reports on Berkeley, California-based Xoma Corp.'s clinical trials of sepsis drug Neuprex, a recombinant human bactericidal/permeability increasing protein, an endogenous neutralizer of endotoxin for the treatment of meningococcal sepsis. Pathogen causing the disease; Comparison of Neuprex with other drugs.